NeuroScientific Biopharmaceuticals Ltd. announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB, achieving a significant milestone in the development of EmtinB as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease. The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | +2.22% | 0.00% | +2.27% |
1st Jan change | Capi. | |
---|---|---|
+2.27% | 4.35M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial